Where Chinese Investors Meet Global Investment News and Opportunities


Redhill Biopharma Ltd (NAS:RDHL)


RedHill Biopharma Ltd. is a NASDAQ listed drug manufacturer based in Israel. The company is focused on late clinical-stage, orally-administered drugs for the treatment of internal inflammatory disorders such as gastroenteritis.

Market Overview

$10.680 (4.090%)
Vol 486,430.00
10 Days Avg Vol 110,392.70
3 Mo Avg Vol 119,191.76
52 Wk Lo/Hi $4.300 - $11.250
YTD Price Gain % 108.19%
12 Wks Moving Avg 6.590678
200 Days Moving Avg 6.342110
Market Cap 217,763,929

Updated: Market Close, 07/13/2018

Company Background

RedHill Biopharma Ltd. is an Israel-based developer of pharmaceutical products addressing multiple diseases. Its primary focus lies on late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of internal inflammatory disorders and cancer. Redhill's assortment of drugs includes RHB-105, which combats the Helicobacter pylori infection; RHB-104, which treats the Crohn's disease and RIZAPORT, for acute migraines. The BEKINDA, YELIVA and MESUPRON were formulated for acute gastroenteritis and other critical inflammatory conditions.


Other Information

Management Profiles

No management profiles found.

Do NOT follow this link or you will be banned from the site!